These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). Cesaro S; Pillon M; Sauer M; Smiers F; Faraci M; de Heredia CD; Wynn R; Greil J; Locatelli F; Veys P; Uyttebroeck A; Ljungman P; Chevalier P; Ansari M; Badell I; Güngör T; Salim R; Tischer J; Tecchio C; Russell N; Chybicka A; Styczynski J; Krivan G; Smith O; Stein J; Afanasyev B; Pochon C; Menconi MC; Bosman P; Mauro M; Tridello G; de Latour RP; Dufour C Bone Marrow Transplant; 2020 Sep; 55(9):1796-1809. PubMed ID: 32203264 [TBL] [Abstract][Full Text] [Related]
3. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen. Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719 [TBL] [Abstract][Full Text] [Related]
4. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081 [TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985 [TBL] [Abstract][Full Text] [Related]
6. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699 [TBL] [Abstract][Full Text] [Related]
7. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856 [TBL] [Abstract][Full Text] [Related]
8. Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Cancio M; Hebert K; Kim S; Aljurf M; Olson T; Anderson E; Burroughs L; Vatsayan A; Myers K; Hashem H; Hanna R; Horn B; Prestidge T; Boelens JJ; Boulad F; Eapen M Transplant Cell Ther; 2022 Feb; 28(2):101.e1-101.e6. PubMed ID: 34670170 [TBL] [Abstract][Full Text] [Related]
9. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study. Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of mismatched and unrelated donor hematopoietic stem cell transplantation in Fanconi anemia conditioned with chemotherapy only. Chao MM; Kuehl JS; Strauss G; Hanenberg H; Schindler D; Neitzel H; Niemeyer C; Baumann I; von Bernuth H; Rascon J; Nagy M; Zimmermann M; Kratz CP; Ebell W Ann Hematol; 2015 Aug; 94(8):1311-8. PubMed ID: 25862235 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. Yoshimi A; Strahm B; Baumann I; Furlan I; Schwarz S; Teigler-Schlegel A; Walther JU; Schlegelberger B; Göhring G; Nöllke P; Führer M; Niemeyer CM Biol Blood Marrow Transplant; 2014 Mar; 20(3):425-9. PubMed ID: 24316460 [TBL] [Abstract][Full Text] [Related]
12. The Case for Upfront HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation as a Curative Option for Adult Acquired Severe Aplastic Anemia. Marsh JCW; Risitano AM; Mufti GJ Biol Blood Marrow Transplant; 2019 Sep; 25(9):e277-e284. PubMed ID: 31129354 [TBL] [Abstract][Full Text] [Related]
13. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298 [TBL] [Abstract][Full Text] [Related]
15. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174 [TBL] [Abstract][Full Text] [Related]
16. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic Stem Cell Transplantation from HLA-Mismatched Donors for Pediatric Patients with Acute Lymphoblastic Leukemia Treated According to the 2003 BFM and 2007 International BFM Studies: Impact of Disease Risk on Outcomes. Dalle JH; Balduzzi A; Bader P; Lankester A; Yaniv I; Wachowiak J; Pieczonka A; Bierings M; Yesilipek A; Sedlaçek P; Ifversen M; Sufliarska S; Toporski J; Glogova E; Poetschger U; Peters C Biol Blood Marrow Transplant; 2018 Sep; 24(9):1848-1855. PubMed ID: 29772352 [TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia. Koyamaishi S; Kamio T; Kobayashi A; Sato T; Kudo K; Sasaki S; Kanezaki R; Hasegawa D; Muramatsu H; Takahashi Y; Sasahara Y; Hiramatsu H; Kakuda H; Tanaka M; Ishimura M; Nishi M; Ishiguro A; Yabe H; Sarashina T; Yamamoto M; Yuza Y; Hyakuna N; Yoshida K; Kanno H; Ohga S; Ohara A; Kojima S; Miyano S; Ogawa S; Toki T; Terui K; Ito E Bone Marrow Transplant; 2021 May; 56(5):1013-1020. PubMed ID: 32948829 [TBL] [Abstract][Full Text] [Related]